|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,043.00 DKK | -6.50% |
|
-5.50% | +0.79% |
| 01-19 | SHB: Overreaction in the Market to Genmab's Epkinly Study | FW |
| 01-19 | Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint | FW |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | DKK 2,150.48 | -1.58% | 13 | ||||||
| €824.2 | +18.83% | 15 | ||||||
| CN¥129.89 | +24.54% | 18 | ||||||
| US$213.94 | +32.54% | 18 | ||||||
| US$119.16 | +26.81% | 19 | ||||||
| HK$36.58 | +2.93% | 25 | ||||||
| HK$154.69 | +42.51% | 21 | ||||||
| HK$532.76 | +12.44% | 17 | ||||||
| US$24.22 | +90.29% | 13 | ||||||
| US$45.61 | +3.76% | 18 | ||||||
| US$612.64 | +22.12% | 14 | ||||||
| US$78.2 | +22.49% | 10 | ||||||
| US$141.71 | +35.92% | 17 | ||||||
| HK$75.1 | -14.14% | 15 | ||||||
| US$88.22 | +40.98% | 18 | ||||||
| - | - | - | - | - | ||||
| Average | 348.49 | +24.03% | 17 | ||||||
| Weighted average by Cap. | 418.39 | +23.26% | 17 |
- Stock Market
- Equities
- GMAB Stock
- Sector Genmab A/S
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition